Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diabetes insipidus05.03.03.004; 14.05.07.0030.001239%-
Diabetes mellitus05.06.01.001; 14.06.01.0010.013259%-
Diarrhoea07.02.01.0010.518075%
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.0040.007311%-
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.004337%
Distractibility19.21.02.0070.001239%-
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.007311%-
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dry throat07.06.01.005; 22.12.03.005---
Duodenal ulcer07.04.02.0020.006815%
Duodenal ulcer haemorrhage07.04.02.004; 24.07.02.0200.003098%-
Duodenal ulcer perforation07.04.02.0030.006196%-
Duodenitis07.08.03.0010.001239%-
Dyspepsia07.01.02.0010.031597%
Dysphagia07.01.06.003--
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.006--
Dysuria20.02.02.0020.011028%
Ear disorder04.03.01.0010.001239%-
Ear infection04.03.01.006; 11.01.05.001---
Eating disorder14.03.01.008; 19.09.01.0080.005576%-
Eczema23.03.04.006--
Electrolyte depletion14.05.01.0010.001239%-
Electrolyte imbalance14.05.01.0020.004337%-
Encephalopathy17.13.02.0010.004956%
Enuresis19.07.04.001; 20.02.02.0030.004213%-
Epilepsy17.12.03.0020.006196%-
Epistaxis22.04.03.001; 24.07.01.0050.021313%
Eructation07.01.02.003--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 18 Pages